SMS Pharma posts 28% profit jump for FY26; dividend is a token ₹0.40
Full-year net profit grew to ₹87.61 crore on 13.3% revenue growth. The market has seen the quarterly build-up already.
— 4 earlier stories on SMS Pharmaceuticals Ltd. →What's new
- FY26 standalone net profit rose 28.1% to ₹87.61 crore on revenue of ₹886.87 crore.
- Board recommends a final dividend of ₹0.40 per share.
- Annual results were disclosed after quarterly updates were already in the public domain.
Why this matters
The numbers themselves are solid: a 28% profit increase on 13.3% revenue growth points to margin improvement. But the results were largely telegraphed by the quarterly disclosures, so the annual filing adds little new information for the market to digest. The dividend is negligible.
What we're watching
- Whether the margin improvement holds in FY27 as revenue scales.
- The board's next move on capital allocation given the modest payout.
- Any commentary on capacity or demand trends from the annual report.
The full read
SMS Pharmaceuticals' FY26 annual results confirm a 28.1% jump in net profit to ₹87.61 crore, driven by 13.3% revenue growth to ₹886.87 crore. The growth profile is clean, with profits outpacing revenue, which points to better cost control. But the filing itself is routine. The quarterly results that comprise these annual figures have already been disclosed, so the market is not learning anything new. The board also recommended a final dividend of ₹0.40 per share, a negligible payout that signals the company is hoarding cash for now rather than rewarding shareholders directly.
Questions answered
- What were SMS Pharma's full-year financial results?
- FY26 standalone revenue from operations was ₹886.87 crore, up 13.3% from ₹782.75 crore in the prior year. Net profit rose 28.1% to ₹87.61 crore, suggesting margin expansion.
- How does the dividend compare to the earnings?
- The board recommends a final dividend of ₹0.40 per share. This is a token payout relative to the ₹87.61 crore net profit, suggesting the company is retaining most of its earnings.
- Why didn't the stock react more to these results?
- The market has already received the underlying quarterly data. This annual filing is a compilation of results that were disclosed sequentially throughout the year, so it contains limited new surprises.
SMS Pharmaceuticals Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on SMSPHARMA →- 22 May 2026 · 1:49 PM IST SMS Pharma posts 28% profit jump for FY26; dividend is a token ₹0.40
- 40d ago SMS Pharmaceuticals cuts FY27 growth target to 15% on geopolitical risk
- 45d ago SMS Pharmaceuticals books ₹87.61 cr annual profit
- 45d ago SMS Pharmaceuticals hits ₹87.61 cr profit as FY26 growth hits target
- 45d ago SMS Pharmaceuticals grows FY26 revenue to ₹886.87 cr